<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Journal of Experimental and Clinical Surgery</journal-id><journal-title-group><journal-title xml:lang="en">Journal of Experimental and Clinical Surgery</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник экспериментальной и клинической хирургии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2070-478X</issn><issn publication-format="electronic">2409-143X</issn><publisher><publisher-name xml:lang="en">Voronezh State Medical University named after N.N. Burdenko</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1010</article-id><article-id pub-id-type="doi">10.18499/2070-478X-2017-10-2-111-115</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Immuno-biological Rationale for the Use of Platelet-rich Donor Plasma for the Regional Treatment of Wounds</article-title><trans-title-group xml:lang="ru"><trans-title>Иммуно-биологическое обоснование применения обогащенной тромбоцитами донорской плазмы для регионального лечения ран</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3575-3726</contrib-id><contrib-id contrib-id-type="spin">5292-5461</contrib-id><name-alternatives><name xml:lang="en"><surname>Corotkich</surname><given-names>Nikolay Nikolaevich</given-names></name><name xml:lang="ru"><surname>Коротких</surname><given-names>Николай Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, deputy head physician of the Voronezh regional clinical hospital №1</p></bio><bio xml:lang="ru"><p>кандидат медицинских наук, заместитель главного врача по хирургии</p></bio><email>3476044@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4257-5120</contrib-id><contrib-id contrib-id-type="spin">8115-2155</contrib-id><name-alternatives><name xml:lang="en"><surname>Aralova</surname><given-names>Maria Valeryevna</given-names></name><name xml:lang="ru"><surname>Аралова</surname><given-names>Мария Валерьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, head. department of ambulatory surgery</p></bio><bio xml:lang="ru"><p>кандидат медицинских наук, заведующая отделением амбулаторно-поликлинической хирургии</p></bio><email>Mashaaralova@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ostroushko</surname><given-names>Anton Petrovich</given-names></name><name xml:lang="ru"><surname>Остроушко</surname><given-names>Антон Петрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, lecturer, Department of General Surgery</p></bio><bio xml:lang="ru"><p>кандидат медицинскх наук, ассистент кафедры общей хирургии</p></bio><email>admin@admin.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2260-7052</contrib-id><contrib-id contrib-id-type="spin">4646-8650</contrib-id><name-alternatives><name xml:lang="en"><surname>Shipilova</surname><given-names>Veronika Vyacheslavovna</given-names></name><name xml:lang="ru"><surname>Шипилова</surname><given-names>Вероника Вячеславовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>head. the blood transfusion</p></bio><bio xml:lang="ru"><p>заведующая отделением переливания крови</p></bio><email>shipilova_v68@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Voronezh State Medical University. N.N. Burdenko "of the Ministry of Health of Russia.</institution></aff><aff><institution xml:lang="ru">Воронежская областная клиническая больница №1</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Voronezh State Medical University. N.N. Burdenko "of the Ministry of Health of Russia.</institution></aff><aff><institution xml:lang="ru">БУЗ ВО Воронежская областная клиническая больница №1</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Voronezh State Medical University. N.N. Burdenko "of the Ministry of Health of Russia.</institution></aff><aff><institution xml:lang="ru">Воронежский государственный медицинский университет имени Н.Н. Бурденко</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2017-09-23" publication-format="electronic"><day>23</day><month>09</month><year>2017</year></pub-date><volume>10</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>111</fpage><lpage>115</lpage><history><date date-type="received" iso-8601-date="2017-06-03"><day>03</day><month>06</month><year>2017</year></date><date date-type="accepted" iso-8601-date="2017-06-03"><day>03</day><month>06</month><year>2017</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2017, Voronezh N.N. Burdenko State Medical University</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2017, ФГБОУ ВО ВГМУ им. Н.Н. Бурденко Минздрава России</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="en">Voronezh N.N. Burdenko State Medical University</copyright-holder><copyright-holder xml:lang="ru">ФГБОУ ВО ВГМУ им. Н.Н. Бурденко Минздрава России</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2017-09-23"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://vestnik-surgery.com/journal/about/editorialPolicies</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnik-surgery.com/journal/article/view/1010">https://vestnik-surgery.com/journal/article/view/1010</self-uri><abstract xml:lang="en"><p>There has recently been great interest in platelet growth factors. Universal mechanism of action, simplicity, low cost and maloinvazivnogo receiving expand their use in practical medicine. However, comorbidities and the technical difficulty of isolating platelets from autoplasma are the limiting factors for widespread adoption of the techniques in the daily work of doctors of most hospitals. The article listed the main drugs of platelets enriched plasma (pure platelet-rich plasma enriched with white blood cells and platelets blood plasma, pure platelet-enriched fibrin enriched with platelets, leukocytes and fibrin), the features, the conditions of their production and hardware by apheresis, and from the pool leykotrieny layers. The marked advantages of automatic separation of blood components, which minimizes the human factor in (avoiding manual labor), allows to distinguish the platelets of high quality with little loss of hemoglobin and plasma, ensures quick and accurate obtaining of necessary blood components and the shelf life of platelets, the importance of timely delivery. The authors considered immune and biological aspects of the use of donor platelet concentrate. Describes methods to reduce the risks of transmission of hemotransmissive infections, alloimmune effects, bacterial contamination of wounds with local application of platelet concentrate. Comparative evaluation of the economic component of the latest hardware by apheresis and from the pool leykotrieny layers. The use of platelet-rich donor plasma for the stimulation of reparative processes in the healing of nonhealing wounds is due to equivalent clinical effectiveness of the use of donor platelet concentrate and platelet-rich autoplasma. Convenience of centralized procurement allows greater use of platelet drugs in many hospitals.</p></abstract><trans-abstract xml:lang="ru"><p>В последнее время отмечается большой интерес к тромбоцитарным факторам роста. Универсальный механизм действия, простота, дешевизна и малоинвазивность получения расширяют их применение в практической медицине. Однако, сопутствующие заболевания и технические трудности выделения тромбоцитов из аутоплазмы являются сдерживающими факторами для широкого внедрения методик в повседневную работу врачей большинства ЛПУ. В статье перечислены основные препараты обогащенной тромбоцитов плазмы (чистая обогащенная тромбоцитами плазма крови, обогащенная лейкоцитами и тромбоцитами плазма крови, чистый обогащенный тромбоцитами фибрин, обогащенный лейкоцитами и тромбоцитами фибрин), отражены особенности, условия их получения и путем аппаратного афереза, и из пула лейкотромбоцитарных слоев. Отмечены плюсы автоматического разделения крови на компоненты, которое минимизирует человеческий фактор (отказ от ручного труда), позволяет максимально выделять тромбоциты высокого качества с малой потерей гемоглобина и плазмы, обеспечивает быстрое и точное получение любых необходимых компонентов крови, и сроки хранения тромбоцитов, важность своевременной доставки. Авторами рассмотрены иммунные и биологические аспекты применения донорского тромбоконцентрата. Описаны методы снижения рисков передачи гемотрансмиссивных инфекций, аллоиммунного воздействия, бактериальной контаминации ран при местном применении тромбоконцентрата. Проведена сравнительная оценка экономической составляющей получения последнего путем аппаратного афереза и из пула лейкотромбоцитарных слоев. Применение обогащенной тромбоцитами донорской плазмы для стимуляции репаративных процессов в длительно незаживающих ранах обусловлено равнозначной клинической эффективностью использования донорского тромбоконцентрата и богатой тромбоцитами аутоплазмы. Удобство централизованной заготовки позволяют более широко использовать препараты тромбоцитов во многих ЛПУ.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>региональное лечение ран</kwd><kwd>аутотромбоконцентрат</kwd><kwd>обогащенная тромбоцитами донорская плазма</kwd><kwd>безопасность</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена в рамках Гранта Президента РФ М К-3494.2017. 7</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1.	Ачкасов Е.Е., Безуглов Э.Н., Ульянов А.А., Куршев В.В., Репетюк А.Д., Егорова О.Н. Применение аутоплазмы, обогащенной тромбоцитами, в клинической практике. Биомедицина. 2013; 4: 46–59.</mixed-citation><mixed-citation xml:lang="ru">1. Ачкасов Е.Е., Безуглов Э.Н., Ульянов А.А., Куршев В.В., Репетюк А.Д., Егорова О.Н. Применение аутоплазмы, обогащенной тромбоцитами, в клинической практике. Биомедицина. 2013; 4: 46–59.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2.	Губанова М.Н., Копченко Т.Г., Жибуpт Е.Б. Выбоp способа получения концентpата тpомбоцитов цельной кpови. Вестник службы крови России. 2009; 3: 20–22.</mixed-citation><mixed-citation xml:lang="ru">2. Губанова М.Н., Копченко Т.Г., Жибуpт Е.Б. Выбоp способа получения концентpата тpомбоцитов цельной кpови. Вестник службы крови России. 2009; 3: 20–22.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3.	Губанова М.Н., Копченко Т.Г., Лиляк М.Ю., Жибурт Е.Б. Заготовка донорской плазмы и аферез тромбоцитов в Ставропольском крае. Трансфузиология. 2014; 15: 3:15–21.</mixed-citation><mixed-citation xml:lang="ru">3. Губанова М.Н., Копченко Т.Г., Лиляк М.Ю., Жибурт Е.Б. Заготовка донорской плазмы и аферез тромбоцитов в Ставропольском крае. Трансфузиология. 2014; 15: 3:15–21.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4.	Жибурт Е.Б., Рейзман П.В., Голосова С.А. Аферез – технология для донора и реципиента. Трансфузиология. 2004; 5:1: 73–83.</mixed-citation><mixed-citation xml:lang="ru">4. Жибурт Е.Б., Рейзман П.В., Голосова С.А. Аферез – технология для донора и реципиента. Трансфузиология. 2004; 5:1: 73–83.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5.	Коденев А.Т., Ващенко Г.А., Капустов В.И., Жибурт Е.Б. Совершенствование получения концентрата тромбоцитов. Вестник службы крови России. 2010; 2: 22–25.</mixed-citation><mixed-citation xml:lang="ru">5. Коденев А.Т., Ващенко Г.А., Капустов В.И., Жибурт Е.Б. Совершенствование получения концентрата тромбоцитов. Вестник службы крови России. 2010; 2: 22–25.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6.	Маланин Д.А., Новочадов В.В., Демкин С.А., Демещенко М.В., Данилов Д.И. Обогащенная тромбоцитами аутологичная плазма в лечении пациентов с гонартрозом III стадии. Травматология и ортопедия России. 2014; 3: 73: 52-59.</mixed-citation><mixed-citation xml:lang="ru">6. Маланин Д.А., Новочадов В.В., Демкин С.А., Демещенко М.В., Данилов Д.И. Обогащенная тромбоцитами аутологичная плазма в лечении пациентов с гонартрозом III стадии. Травматология и ортопедия России. 2014; 3: 73: 52-59.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7.	Мастыков А.Н., Дейкало В.П., Самсонова И.В., Болобошко К.Б. Эффективность применения обогащенной тромбоцитами плазмы при лечении травматических дефектов хряща суставных поверхностей. Новости хирургии. 2013;21: 3-9.</mixed-citation><mixed-citation xml:lang="ru">7. Мастыков А.Н., Дейкало В.П., Самсонова И.В., Болобошко К.Б. Эффективность применения обогащенной тромбоцитами плазмы при лечении травматических дефектов хряща суставных поверхностей. Новости хирургии. 2013;21: 3-9.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8.	Султанбаев У.С., Аюпова Р.Ф., Стрельникова Е.В. Заготовка и обеспечение безопасности донорских тромбоцитов в Республике Башкортостан. Трансфузиология. 2015; 16:2: 16–21.</mixed-citation><mixed-citation xml:lang="ru">8. Султанбаев У.С., Аюпова Р.Ф., Стрельникова Е.В. Заготовка и</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9.	Burnouf T., Strunk D., Koh M.B., Schallmoser K. Human platelet lysate: Replacing fetal bovine serum as a gold standard for human cell propagation? Biomaterials. 2016; 76: 371-87.</mixed-citation><mixed-citation xml:lang="ru">обеспечение безопасности донорских тромбоцитов в Республике Башкортостан. Трансфузиология. 2015; 16:2: 16–21.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10.	Cognasse F., Hamzeh-Cognasse H., Lafarge S. et al. Donor platelets stored for at least 3 days can elicit activation marker expression by the recipient’s blood mono¬nuclear cells: an in vitro study. Transfusion. 2009; 49:1: 91-98.</mixed-citation><mixed-citation xml:lang="ru">9. Burnouf T., Strunk D., Koh M.B., Schallmoser K. Human platelet</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11.	Dohan Ehrenfest D.M., Rasmusson L., Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L- PRF). Trends Biotechnol. 2009; 27: 158-167.</mixed-citation><mixed-citation xml:lang="ru">lysate: Replacing fetal bovine serum as a gold standard for human cell propagation? Biomaterials. 2016; 76: 371-87.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12.	Foster TE, Puskas BL, Mandelbaum BR, et all. Platelet-rich plasma: from basic science to clinical applications. Am J Sports Med. 2009; 37: 2259–2272.</mixed-citation><mixed-citation xml:lang="ru">10. Cognasse F., Hamzeh-Cognasse H., Lafarge S. et al. Donor platelets stored for at least 3 days can elicit activation marker expression by the recipient’s blood mononuclear</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13.	Garraud O., Cognasse F., Tissot J.D. et al. Improving platelet transfusion safety: biomedical and technical considerations. Blood Transfus. 2015;16: 1-14.</mixed-citation><mixed-citation xml:lang="ru">cells: an in vitro study. Transfusion. 2009; 49:1: 91-98.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14.	Kasemkijwattana C, Menetrey J, Bosch P, et all. Use of growth factors to improve muscle healing after strain injury. Clin Orthop Relat Res. 2000; 370:272–285.</mixed-citation><mixed-citation xml:lang="ru">11. Dohan Ehrenfest D.M., Rasmusson L., Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L- PRF). Trends Biotechnol. 2009;27: 158-167.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Lafeuillade B., Eb F., Ounnoughene N. et al. Residual risk and retrospective analysis of transfusion-transmitted bacterial infection reported by the French National Hemovigilance Network from 2000 to 2008. Transfusion. 2015; 55: 3: 636-46.</mixed-citation><mixed-citation xml:lang="ru">12. Foster TE, Puskas BL, Mandelbaum BR, et all. Platelet-rich plasma: from basic science to clinical applications. Am J Sports Med. 2009;37: 2259–2272.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Molloy T, Wang Y, Murrell G. The roles of growth factors in tendon and ligament healing. Sports Med. 2003; 33:381–394.</mixed-citation><mixed-citation xml:lang="ru">13. Garraud O., Cognasse F., Tissot J.D. et al. Improving platelet</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17.	Nagumo A, Yasuda K, Numazaki H, et all. Effects of separate application of three growth factors (TGF-beta1, EGF, and PDGF-BB) on mechanical properties of the in situ frozenthawed anterior cruciate ligament. Clin Biomech. 20005; 20:283–290.</mixed-citation><mixed-citation xml:lang="ru">transfusion safety: biomedical and technical considerations. Blood Transfus. 2015;16: 1-14.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18.	Pearson H., Davis K.G., Wood E.M. et al. Logistics of platelet concentrates. Vox Sanguinis. 2007; 92: 2: 160–181.</mixed-citation><mixed-citation xml:lang="ru">14. Kasemkijwattana C, Menetrey J, Bosch P, et all. Use of growth factors to improve muscle healing after strain injury. Clin Orthop Relat Res. 2000; 370:272–285.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19.	Pujol JP, Chadjichristos C, Legendre F, et all. Interleukin-1 and transforming growth factor-beta 1 as crucial factors in osteoarthritic cartilage metabolism. Connect Tissue Res. 2008; 49:293–297.</mixed-citation><mixed-citation xml:lang="ru">15. Lafeuillade B., Eb F., Ounnoughene N. et al. Residual risk and</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20.	Sandgren P., Diedrich B. Pathogen inactivation of double-dose buffy-coat platelet concentrates photochemically treated with amotosalen and UVA light: preservation of in vitro function. Vox Sang. 2015; 108(4): 340-349.</mixed-citation><mixed-citation xml:lang="ru">retrospective analysis of transfusion-transmitted bacterial infection</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">21.	Seghatchian J. Multilayer-strategy to enhance optimal safety of the blood supply: The role of pathogen inactivation for optimizing recipient safety and helping health care cost containment: Moderator views. Transfus Apher Sci. 2015; 52:2: 233-6.</mixed-citation><mixed-citation xml:lang="ru">reported by the French National Hemovigilance Network from 2000 to 2008. Transfusion. 2015; 55: 3: 636-46.</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">22.	Sаnchez M, Anitua E, Azofra J, et all. Intraarticular injection of an autologous preparation rich in growth factors for the treatment of knee OA: a retrospective cohort study. Clin Exp. Rheumatol. 2008; 26:910–913.</mixed-citation><mixed-citation xml:lang="ru">16. Molloy T, Wang Y, Murrell G. The roles of growth factors in tendon and ligament healing. Sports Med. 2003; 33:381–394.</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><mixed-citation>17. Nagumo A, Yasuda K, Numazaki H, Azuma H., Tanabe Y., Kikuchi S., Harata S., Tohyama H. Effects of separate application of three growth factors (TGF-beta1, EGF, and PDGF-BB) on mechanical properties of the in situ frozenthawed anterior cruciate ligament. Clin Biomech. 2005; 20:283–290.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>18. Pearson H., Davis K.G., Wood E.M. Logistics of platelet concentrates. Vox Sanguinis. 2007; 92: 2: 160–181.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>19. Pujol JP, Chadjichristos C, Legendre F, Bauge C., Beauchef G.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Interleukin-1 and transforming growth factor-beta 1 as crucial factors in osteoarthritic cartilage metabolism. Connect Tissue Res. 2008;49:293–297.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>20. Sandgren P., Diedrich B. Pathogen inactivation of double-dose buffycoat platelet concentrates photochemically treated with amotosalen and UVA light: preservation of in vitro function. Vox Sang. 2015; 108(4): 340-349.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>21. Seghatchian J. Multilayer-strategy to enhance optimal safety of</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>the blood supply: The role of pathogen inactivation for optimizing</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>recipient safety and helping health care cost containment: Moderator views. Transfus Apher Sci. 2015; 52:2: 233-6.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>22. Sаnchez M, Anitua E, Azofra J, Aquirre J., Andia I. Intraarticular</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>injection of an autologous preparation rich in growth factors for</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>the treatment of knee OA: a retrospective cohort study. Clin Exp.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Rheumatol. 2008; 26:910–913.</mixed-citation></ref></ref-list></back></article>
